The Global Drug Discovery Technologies Market is poised to grow at a CAGR of around 12.2% over the next decade to reach approximately $160 billion by 2025.
This industry report analyzes the market estimates and forecasts for all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies.
Some of the prominent trends that the market is witnessing include growing identification of combinatorial chemistry technology, regulatory initiatives fostering demand for pharmacogenomics technology, proteomics in anticancer drug discovery and human protein microarray for various protein analysis.
Based on technology the market is categorized into pharmacogenomics, high throughput screening, genomics, bioinformatics, biochips, bioanalytical Instruments, nanotechnology, metabolomics and other technologies. Depending on the end users the market is segmented by research institutes, pharmaceutical companies, biotech companies, biopharmaceutical companies and other end users.
Depending on the Applications the market is segmented by cardiovascular diseases, cancer Parkinson's disease, central nervous system disorders and other applications.
- The report provides a detailed analysis on current and future market trends to identify the investment opportunities - Market forecasts till 2025, using estimated market values as the base numbers - Key market trends across the business segments, Regions and Countries - Key developments and strategies observed in the market - Market Dynamics such as Drivers, Restraints, Opportunities and other trends - In-depth company profiles of key players and upcoming prominent players - Growth prospects among the emerging nations through 2025 - Market opportunities and recommendations for new investments
3 Market Overview 3.1 Current Trends 3.1.1 Growing identification of combinatorial chemistry technology 3.1.2 Regulatory initiatives fostering demand for pharmacogenomics technology 3.1.3 Proteomics in anticancer drug discovery 3.1.4 Human protein microarray for various protein analysis 3.2 Drivers 3.3 Constraints 3.4 Industry Attractiveness
4 Drug Discovery Technologies Market, By Technology Type 4.1 Pharmacogenomics 4.2 High Throughput Screening 4.3 Genomics 126.96.36.199 Structural Genomics 188.8.131.52 Functional Genomics 184.108.40.206 Other Genomics technologies 220.127.116.11.1.1 Clinical Medicine 18.104.22.168.1.2 New Antibiotics 4.4 Bioinformatics 22.214.171.124 Computer-Aided Drug Design 4.5 Biochips 126.96.36.199 Lab on a chip 188.8.131.52 Proteomics microarrays 184.108.40.206 DNA and Protein microarrays 4.6 Bioanalytical Instruments 220.127.116.11 Chemotherapy instruments 18.104.22.168 Mass spectrometry 22.214.171.124 Microplate readers 126.96.36.199 Nuclear magnetic resonance 4.7 Nanotechnology 188.8.131.52 Nano-mass spectroscopy 184.108.40.206 Dip-pen Nanolithography 220.127.116.11 Atomic force microscopy (AFM) 4.8 Metabolomics 18.104.22.168 Target Identification 22.214.171.124 Target Validation 126.96.36.199 Lead Optimization 188.8.131.52 Mode of Action 184.108.40.206 Preclinical Studies 220.127.116.11 Clinical Studies 18.104.22.168 Post-Approval Studies 22.214.171.124 Diagnostics 4.9 Other Technologies 126.96.36.199 RNAi (RNA interference) 188.8.131.52.1.1 MiRNAS (MicroRNA sequencing) 184.108.40.206.1.2 SiRNA (Small interfering RNA) 220.127.116.11.1.3 Other RNAi technologies 18.104.22.168 Combinatorial chemistry 22.214.171.124.1.1 Chemical Encoding 126.96.36.199.1.2 Positional Encoding 188.8.131.52.1.3 Electronic Encoding 184.108.40.206 Synthetic Biology 220.127.116.11 Proteomic 18.104.22.168.1.1 Two dimensional gel electrphoresis- 2DGE 22.214.171.124.1.2 Two-hybrid systems 126.96.36.199 Cell Based Assays 188.8.131.52 Epigenetics 184.108.40.206 Systems Biology 220.127.116.11.1.1 Computer Modelling 18.104.22.168 Quantitative polymerase chain reaction (QPCR) 22.214.171.124 Laboratory information management systems 126.96.36.199 Microfluidics 188.8.131.52 Chromatography 184.108.40.206 Protein and nucleic acid isolation
5 Drug Discovery Technologies Market, By End User 5.1 Research Institutes 5.2 Pharmaceutical Companies 5.3 Biotech Companies 5.4 Biopharmaceutical Companies 5.5 Other End Users
6 Drug Discovery Technologies Market, By Application 6.1 Cardiovascular Diseases 6.2 Cancer 6.3 Parkinson's disease 6.4 Central Nervous System Disorders 6.5 Other Applications 6.5.1 Other Applications Market Forecast to 2025 (US$ MN)
7 Drug Discovery Technologies Market, By Geography
8 Key Player Activities 8.1 Acquisitions & Mergers 8.2 Agreements, Partnerships, Collaborations and Joint Ventures 8.3 Product Launch & Expansions 8.4 Other Activities
9 Leading Companies
- Affymetrix Inc. - Tecan Group Ltd. - Sigma-Aldrich Corp - Shimadzu Corp - Perkinelmer Inc. - Thermo Fisher Scientific Inc. - Incyte Corp - Gyros AB - F. Hoffmann-La Roche Ltd. - Evotec AG - Chembridge Corp - Abbott Laboratories Inc. - Celera Corp - Caliper Life Sciences Inc. - Bio-Rad Laboratories Inc. - Astrazeneca Plc. - Albany Molecular Research Inc. - Agilent Technologies Inc. - Charles River Laboratories International Inc. - Life Technologies Corp